tetano
Editor, Senior Moderator
Sci Rep
. 2023 Nov 28;13(1):20936.
doi: 10.1038/s41598-023-47547-1. Generation of "OP7 chimera" defective interfering influenza A particle preparations free of infectious virus that show antiviral efficacy in mice
Tanya Dogra[SUP] 1 [/SUP], Lars Pelz[SUP] 1 [/SUP], Julia D Boehme[SUP] 2 3 [/SUP], Jan Kuechler[SUP] 1 [/SUP], Olivia Kershaw[SUP] 4 [/SUP], Pavel Marichal-Gallardo[SUP] 1 [/SUP], Maike Baelkner[SUP] 2 3 [/SUP], Marc D Hein[SUP] 5 [/SUP], Achim D Gruber[SUP] 4 [/SUP], Dirk Benndorf[SUP] 1 5 [/SUP], Yvonne Genzel[SUP] 1 [/SUP], Dunja Bruder[SUP] 2 3 [/SUP], Sascha Y Kupke[SUP] 6 [/SUP], Udo Reichl[SUP] 1 5 [/SUP]
Affiliations
Influenza A virus (IAV) defective interfering particles (DIPs) are considered as new promising antiviral agents. Conventional DIPs (cDIPs) contain a deletion in the genome and can only replicate upon co-infection with infectious standard virus (STV), during which they suppress STV replication. We previously discovered a new type of IAV DIP "OP7" that entails genomic point mutations and displays higher antiviral efficacy than cDIPs. To avoid safety concerns for the medical use of OP7 preparations, we developed a production system that does not depend on infectious IAV. We reconstituted a mixture of DIPs consisting of cDIPs and OP7 chimera DIPs, in which both harbor a deletion in their genome. To complement the defect, the deleted viral protein is expressed by the suspension cell line used for production in shake flasks. Here, DIP preparations harvested are not contaminated with infectious virions, and the fraction of OP7 chimera DIPs depended on the multiplicity of infection. Intranasal administration of OP7 chimera DIP material was well tolerated in mice. A rescue from an otherwise lethal IAV infection and no signs of disease upon OP7 chimera DIP co-infection demonstrated the remarkable antiviral efficacy. The clinical development of this new class of broad-spectrum antiviral may contribute to pandemic preparedness.
. 2023 Nov 28;13(1):20936.
doi: 10.1038/s41598-023-47547-1. Generation of "OP7 chimera" defective interfering influenza A particle preparations free of infectious virus that show antiviral efficacy in mice
Tanya Dogra[SUP] 1 [/SUP], Lars Pelz[SUP] 1 [/SUP], Julia D Boehme[SUP] 2 3 [/SUP], Jan Kuechler[SUP] 1 [/SUP], Olivia Kershaw[SUP] 4 [/SUP], Pavel Marichal-Gallardo[SUP] 1 [/SUP], Maike Baelkner[SUP] 2 3 [/SUP], Marc D Hein[SUP] 5 [/SUP], Achim D Gruber[SUP] 4 [/SUP], Dirk Benndorf[SUP] 1 5 [/SUP], Yvonne Genzel[SUP] 1 [/SUP], Dunja Bruder[SUP] 2 3 [/SUP], Sascha Y Kupke[SUP] 6 [/SUP], Udo Reichl[SUP] 1 5 [/SUP]
Affiliations
- PMID: 38017026
- DOI: 10.1038/s41598-023-47547-1
Influenza A virus (IAV) defective interfering particles (DIPs) are considered as new promising antiviral agents. Conventional DIPs (cDIPs) contain a deletion in the genome and can only replicate upon co-infection with infectious standard virus (STV), during which they suppress STV replication. We previously discovered a new type of IAV DIP "OP7" that entails genomic point mutations and displays higher antiviral efficacy than cDIPs. To avoid safety concerns for the medical use of OP7 preparations, we developed a production system that does not depend on infectious IAV. We reconstituted a mixture of DIPs consisting of cDIPs and OP7 chimera DIPs, in which both harbor a deletion in their genome. To complement the defect, the deleted viral protein is expressed by the suspension cell line used for production in shake flasks. Here, DIP preparations harvested are not contaminated with infectious virions, and the fraction of OP7 chimera DIPs depended on the multiplicity of infection. Intranasal administration of OP7 chimera DIP material was well tolerated in mice. A rescue from an otherwise lethal IAV infection and no signs of disease upon OP7 chimera DIP co-infection demonstrated the remarkable antiviral efficacy. The clinical development of this new class of broad-spectrum antiviral may contribute to pandemic preparedness.